Cambrex Expands Biopharmaceutical Services Business
PR94683
EAST RUTHERFORD, N.J. , March 1, 2022 /PRNewswire=KYODO JBN/ --
Cambrex, a leading global contract development and manufacturing organization
(CDMO) providing drug substance, drug product, and analytical services across
the entire drug lifecycle, today announced it is significantly expanding its
existing biopharmaceutical testing services business. The expansion includes 11
additional cGMP laboratories at Cambrex's Durham, NC facility and broadens its
service offering for large molecule and viral/cell-based therapeutics.
"We are excited to be adding to our fast-growing biopharmaceutical services
business.," said Cambrex CEO Thomas Loewald. "Building upon the strength of our
analytical team in Durham, this expansion enables us to increase our capacity
to serve the large and growing biologics market, supporting the development and
testing of a rapidly growing pipeline of large molecule therapeutics."
The expansion includes a range of new instruments supporting nanoparticle size
analysis, imaging, qPCR, fluorescent/absorbance plate readers, immunoblotting,
mass spectrometry, next-generation sequencing (NGS), chromatography capillary
electrophoresis (CE-PDA and FLD), SEC-MALS, and other compendial testing.
These new capabilities apply to a wide variety of biopharmaceutical
therapeutics, including bacteriophage and mammalian viruses, recombinant
proteins, monoclonal antibodies, and nucleic acids. Additionally, Cambrex
recently installed a new 600 MHz NMR spectrometer to enhance support for both
biopharmaceutical and small molecule programs. Combining these new capabilities
with their existing services, Cambrex is now positioned to provide analytical
services throughout the lifecycle of small and large molecule therapeutics.
About Cambrex
Cambrex is a leading global contract development and manufacturing organization
(CDMO) that provides drug substance, drug product, and analytical services
across the entire drug lifecycle. With over 40 years of experience and a
growing team of over 2,200 experts servicing global clients from North America
and European sites, Cambrex is a trusted partner in branded and
generic markets for API and dosage form development and manufacturing.
Cambrex offers a range of specialized drug substance technologies and
capabilities, including biocatalysts. Continuous flow, controlled substances,
solid-state science, material characterization, and highly potent APIs. In
addition, Cambrex can support conventional dosage forms, including oral solids,
semi-solids, and liquids, and has the expertise to manufacturespecialty dosage
forms such as modified-release, fixed-dose combination, pediatric, bi-layer
tablets, stick packs, topicals, controlled substances, sterile and non-sterile
ointments.
For more information, visit www.cambrex.com
Logo - https://mma.prnewswire.com/media/1723116/Cambrex_40_Years_Logo.jpg
Source: Cambrex
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。